Biogen

Biogen Inc. is a leading American multinational biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative therapies for neurological, neurodegenerative, and autoimmune diseases. Founded in 1978 by a group of prominent scientists including Walter Gilbert and Phillip Sharp, both Nobel Prize winners, Biogen has established itself as a pioneer in biotechnology and neuroscience research. The company's primary focus areas include multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). Biogen's flagship products include Tecfidera, Avonex, and Plegridy for multiple sclerosis treatment, as well as Aduhelm (aducanumab), the controversial Alzheimer's drug that received FDA approval in 2021. The company operates through a global network of manufacturing facilities, research centers, and commercial operations spanning North America, Europe, and Asia-Pacific regions. Biogen has built strategic partnerships with leading academic institutions and pharmaceutical companies to advance cutting-edge research in neuroscience and biosimilars. With over 7,800 employees worldwide, the company invests heavily in research and development, dedicating approximately 20% of its revenue to R&D activities. Biogen is publicly traded on NASDAQ and has been recognized for its commitment to environmental sustainability and corporate responsibility initiatives.